In The News
News Release

Cricket Health Secures $83.5 Million Series B Funding Round Supported by Industry-Leading Clinical Outcomes

Share this story:

Round Led By Valtruis, a Welsh, Carson, Anderson & Stowe Portfolio Company, with Investments from Health Plan Customers


San Francisco, CA (August 5, 2021), PR Newswire Today, Cricket Health announced it has closed an $83.5 million Series B funding round led by Valtruis. The round also includes existing investors Oak HC/FT and Cigna Ventures, as well as K2 HealthVentures and a strategic investment from an established not-for-profit health plan. The funding round will enable Cricket Health’s rapid expansion to support growing demand for its proven care model for people with kidney disease across the United States.

“Kidney disease has been a tremendous problem for our health care system due to its complexity, high cost of care, and the lack of early diagnosis intervention. Cricket Health’s approach of marrying cutting edge analytics with dedicated care teams supported by a digital health platform is achieving outstanding clinical outcomes,” said Tracy Bahl, Managing Partner at Valtruis, which is focused on investing in companies with value-based and health-at-home models. “We are excited to help Cricket Health continue to expand its reach and positively impact the lives of even more Americans with kidney disease.”

Cricket Health has developed a track record of improving clinical outcomes for people with kidney disease, which in turn results in lower costs for health plan partners. In both Texas and California, across Commercial and Medicare Advantage health plan partnerships, Cricket Health has shown marked improvements in key clinical measures for its populations living with kidney disease, including:

  • More than 50 percent fewer hospital admissions than the status quo;
  • 77 percent of those starting dialysis do so in an outpatient setting (compared to the status quo of 40 percent);
  • 45 percent who need dialysis are initiating at home (compared to the status quo of 11 percent); and
  • 60 percent of those starting dialysis do so with a permanent access placed (compared to the status quo of 45 percent).

“In our partnership with Cricket, we’ve been able to bring even more affordability, predictability and simplicity to our customers with kidney disease,” said Tom Richards, Senior Vice President and Global Lead, Strategy and Business Development at Cigna. “Since May 2020, we’ve seen more than a 50 percent reduction in hospitalizations and an increase in patient autonomy in a customer’s transition to dialysis, and we look forward to continuing our partnership to help improve our customers’ experience and their health.”

Through its StageSmart™ predictive analytics model, Cricket Health is able to identify patients with chronic kidney disease stages 3b and beyond with 96 percent accuracy. This allows Cricket Health to risk stratify patient populations for plans and providers and deliver stage-specific care to those who need it most. Cricket Health extends care delivery capabilities through the MyCricket™ comprehensive patient support service, which includes a multidisciplinary care team, peer support, and educational resources available any time virtually, as well as by telephone or in person when needed. If patients do progress to end-stage kidney disease (ESKD), Cricket Health’s evidence-based approach increases transplant referrals, increases utilization of home dialysis, and reduces unnecessary hospitalizations.

“Changing the way kidney disease is identified and managed is how we are able to deliver better clinical results,” said Robert Sepucha, Cricket Health CEO. “By identifying patients earlier and delivering the care they need, we are helping more Americans than ever stay healthy, at home, and out of the hospital. With new partners Welsh Carson and existing partners Oak HC/FT, Cigna, and K2 Health Ventures, we will be able to continue to expand our innovative model of kidney care across the country.”

With the new funding, Cricket Health has raised a total of more than $120 million in equity and debt financing to date.

About Cricket Health
Cricket Health is an industry-leading provider of value-based kidney care with a clinically-proven approach to managing chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Cricket Health helps payers and providers shift their entire approach to kidney disease upstream, enabling them to intervene early and deliver stage-specific care to those who need it most, ultimately reducing costs and improving kidney disease outcomes. Cricket Health uses the StageSmart™ machine learning model and predictive GFR (pGFR™) to risk stratify a patient population across each stage of kidney disease with 96 percent accuracy for people with stage 3b and beyond and then delivers individualized care through its comprehensive patient support service, MyCricketTM. Cricket Health members have access to educational resources, peer support, and a multidisciplinary care team in person, by telephone, and virtually. Founded in 2015 and based in San Francisco and Cambridge, the company’s leadership includes some of the leading experts in nephrology, health care, and technology. Learn more at or follow us @crickethealth.

About Valtruis
Valtruis, a WCAS portfolio company, provides a unique platform that invests in and partners with disruptive leaders whose mission is to align and transform healthcare through what is truly value-based care. Founded on a commitment to accelerate meaningful change, Valtruis brings the functional expertise, access to capital and an expansive network that advance our partners’ evolution from early-stage development to industry-leading enterprises. Together, Valtruis and its partner companies will break through the systemic barriers in the healthcare industry to reduce costs, expand access, increase quality and radically improve the patient experience. Learn more at

What's New